AlloHCT From Matched Unrelated Donors in Pts w/ Advanced Hematologic Malignancies & Disorders

Lymphoma Clinical Trial

Official title:

Allogeneic Stem Cell Transplantation for Patients With Hematological Malignancies Using Multiple Unrelated Cord Blood Units

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00547196
• Other study ID #: 02165
• Secondary ID: P30CA033572CHNMC
• Status: Completed
• Phase: N/A
• Start date: August 16, 2005
• Est. completion date: May 28, 2024

Study information

• Verified date: June 2024
• Source: City of Hope Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Giving chemotherapy with or without total-body irradiation before a donor umbilical cord blood transplant helps stop the growth of cancer or abnormal cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. When the stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving cyclosporine and mycophenolate mofetil before and after transplant may stop this from happening.

PURPOSE: This clinical trial is studying how well four different chemotherapy regimens given with or without total-body irradiation before umbilical cord blood transplant work in treating patients with relapsed or refractory hematologic cancer.

Description:

OBJECTIVES:

Primary

• To determine the survival at day 100 of patients with relapsed, refractory, or poor-risk hematological malignancies treated with four different preparative regimens followed by allogeneic hematopoietic stem cell transplantation (HSCT) using two unrelated umbilical cord blood (UCB) units.

Secondary

• To determine the incidence and timing of neutrophil engraftment in patients treated with these regimens.

• To determine the incidence and timing of platelet engraftment in patients treated with these regimens.

• To determine the incidence and severity of acute and chronic graft-versus-host-disease (GVHD) in patients treated with these regimens.

• To determine the survival at day 180 in patients treated with these regimens.

• To determine the disease-free survival in patients treated with these regimens.

• To determine the incidence of primary and secondary engraftment failure in patients treated with these regimens.

• To determine the incidence of transplantation-related complications (e.g., infection, veno-occlusive disease of the liver, or organ toxicity) in these patients.

• To determine the incidence of post-transplantation-related lymphoproliferative disease, secondary myelodysplastic syndromes, or other secondary malignancies in these patients.

• To determine the incidence of relapse in patients treated with these regimens.

• To determine post-transplantation chimerism in patients treated with these regimens.

• To determine immune reconstitution in patients treated with these regimens.

OUTLINE: This is a multicenter study.

• Preparative regimens: Patients are assigned to 1 of 4 preparative regimens.

• Regimen 1 (for patients < 50 years of age and no contraindication to fractionated total-body irradiation (FTBI): Patients undergo FTBI 2-3 times a day on days -9 to -6 for a total of 11 fractions. Patients also receive cyclophosphamide IV over 2 hours on days -5 and -4 and fludarabine phosphate IV on days -5 to -2.

• Regimen 2 (for patients < 50 years of age and unable to tolerate FTBI due to prior dose-limiting radiotherapy or significant cardiotoxicity): Patients receive a test dose of busulfan on day -10 and then dose adjusted busulfan IV 3-4 times daily on days -9 to -6, melphalan IV on days -5 and -4, and fludarabine phosphate IV on days -5 to -2.

• Regimen 3* (for patients unable to tolerate regimen 1 or 2; no age exclusion):

Patients receive fludarabine phosphate IV on days -8 to -4 and cyclophosphamide IV over 2 hours on day -3 and undergo TBI (single dose) on day -2.

• Regimen 4* (for patients unable to tolerate regimen 1 or 2): Patients receive fludarabine phosphate IV on days -7 to -3 and melphalan IV on day -2.

NOTE: *Treating physician decides the choice between regimen 3 and 4

• Umbilical cord blood (UCB) transplantation: Patients receive 2 combined units of UCB IV on day 0. Patients also receive G-CSF IV or subcutaneously beginning on day 5 (or later) and continuing until blood counts recover.

• Graft-versus-host-disease prophylaxis: Patients receive cyclosporine IV twice daily beginning on day -1 followed by a taper according to institutional guidelines. Patients also receive mycophenolate mofetil orally or IV beginning on day 0 and continuing until day 27 (or as clinically indicated).

After completion of study therapy, patients are followed periodically.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 10
• Est. completion date: May 28, 2024
• Est. primary completion date: November 11, 2009
• Accepts healthy volunteers: No
• Gender: All
• Age group: 0 Years to 120 Years

Eligibility

DISEASE CHARACTERISTICS:

• Histologically confirmed hematological or lymphatic malignancy, including any of the following:

• Acute myeloid leukemia

• Relapsed or primary refractory disease with < 10% blasts on peripheral blood smear

• In first remission with poor risk factors and molecular prognosis [i.e., AML with -5, -7, t(6;9), tri8, -11] (preparative regimen 3 or 4)

• Acute lymphocytic leukemia

• In second complete remission or higher OR in first remission with poor risk factors, including any of the following (preparative regimen 1 or 2):

• BCR/ABL by fluorescence in situ hybridization (FISH) or reverse transcriptase-polymerase chain reaction

• t(9;22)(q34;q11) detected by cytogenetics

• Chromosomes < 44 by cytogenetics

• DNA index < 0.81 by flow cytometry

• Any rearrangement of chromosome 11 that results in disruption of MLL gene (11q23) by cytogenetics and SER

• In first remission with poor risk factors and molecular prognosis [ALL with Philadelphia chromosome-positive t(9;22), t(4;22), (q34;q11)] (preparative regimen 3 or 4)

• Chronic myelogenous leukemia

• In accelerated phase or greater (preparative regimen 1 or 2)

• In accelerated or second chronic phase (preparative regimen 3 or 4)

• Myelodysplastic syndromes

• With deletion of chromosome 7 or short arm of chromosome 5 (preparative regimen 1 or 2)

• In high and high-intermediate risk categories (preparative regimen 3 or 4)

• Non-Hodgkin lymphoma in relapse with marrow involvement

• Refractory chronic lymphocytic leukemia

• Patients deemed ineligible for conventional high-dose chemotherapy programs (i.e., regimens 1 or 2) due to any of the following concurrent medical conditions may be eligible for regimens 3 or 4 at the discretion of the treating physician and principal investigator (preparative regimen 3 or 4):

• LVEF < 50% and > 40%

• FEV1, FVC, or DLCO < 50%

• Bilirubin > 3 mg/dL

• Creatinine > 2 mg/dL

• Two partially HLA-matched umbilical cord blood (UCB) units available

• HLA-matched minimally at 4 of 6 HLA-A, HLA-B, and -DRB1 loci with the patient

• DRB1 matched by high resolution DNA typing

• HLA-A and HLA-B matched by low resolution at the "serological match" level

• Two pooled units with a nucleated cell number > 2.5 x 10^7/kg

• No available HLA-identical sibling or 1 antigen-mismatched related donor

• No available HLA-matched unrelated bone marrow donor

PATIENT CHARACTERISTICS:

• See Disease Characteristics

• Karnofsky performance status (PS) 60-100% OR Lansky PS 60-100% OR Zubrod PS 0-1

• Physiological age 60 or less (at any chronological age)

• Weight > 50 kg

• Creatinine normal for age OR creatinine clearance by 24-hour urine collection or glomerular filtration rate > 60 mL/min

• Bilirubin = 1.5 mg/dL

• LVEF = 50%

• DLCO = 60% of predicted

• No HIV-1 infection

• No active uncontrolled infection

• Not pregnant

• Negative pregnancy test

• Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

• Recovered from prior intensive chemotherapy

Related Conditions & MeSH terms

• Leukemia
• Lymphoma
• Myelodysplastic Syndromes
• Preleukemia
• Syndrome

Intervention

Biological:
• filgrastim

Drug:
• Busulfan

• Cyclophosphamide

• Cyclosporine

• Fludarabine phosphate

• Melphalan

• Mycophenolate Mofetil

Procedure:
• allogeneic hematopoietic stem cell transplantation

• umbilical cord blood transplantation

Radiation:
• total-body irradiation

• Fractionated total body irradiation

Locations

Country	Name	City	State
United States	City of Hope Medical Center	Duarte	California
United States	Banner Good Samaritan Medical Center	Phoenix	Arizona

Sponsors (2)

Lead Sponsor	Collaborator
City of Hope Medical Center	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Survival Rate at Day 100 After Allogeneic Transplant From Umbilical Cord Blood (UCB)	Number of surviving patients at Day 100 post-transplant divided by number of patients undergone transplantation.	From transplant to Day 100 post-transplant
Secondary	Survival Rate at Day 180 After Allogeneic Transplant From Umbilical Cord Blood (UCB)	Number of surviving patients at Day 180 post-transplant divided by number of patients undergone transplantation.	From transplant up to Day 180 post-transplant